Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002-Reference-Cited by-同舟云学术

Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002

Published:1997-03 Issue:3 Volume:157 Page:929-934
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Iversen Peter¹,Rasmussen Finn¹,Asmussen Christian¹,Christensen Ib J.¹,Eickhoff Jens¹,Klarskov Peter¹,Larsen Erik¹,Mogensen Peter¹,Mommsen Soren¹,Rosenkilde Palle¹

Affiliation:

1. Danish Prostatic Cancer Group (DAPROCA) and Departments/Sections of Urology, Hvidovre Hospital, Herlev Hospital, Rigshospitalet, Aalborg Hospital Nord, Gentofte Hospital, Bispebjerg Hospital, Glostrup Hospital, Odense Hospital, Naestved Hospital and Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference26 articles.

1. The management of carcinoma of the prostate after failed primary therapy;Howard;Brit. J. Urol.,1993

2. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma;Eisenberger;Urol. Clin. N. Amer.,1987

3. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?;Tannock;J. Clin. Oncol.,1985

4. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells;Stearns;J. Cell. Biol.,1988

5. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents;Tew;Urology,1984

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies;Clinical Genitourinary Cancer;2018-04

2. Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2016-10

3. Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment;Journal of Clinical Oncology;2014-01-20

4. End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review;World Journal of Methodology;2014

5. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature;Medical Oncology;2013-09-05